Santen to acquire InnFocus

Santen Pharmaceutical announced it has entered into a definitive agreement to acquire InnFocus, developer of the MicroShunt glaucoma implant device.Santen will acquire InnFocus for an upfront payment of $225 million, plus performance-based considerations upon achievement of development, commercial and regulatory milestones, according to a press release.

Full Story →